Northwest Biotherapeutics (NWBO) 8.36 $NWBO
Interesting NWBO Put And Call Options For June 19th
StockOptionsChannel.com - Wed Apr 22, 10:19AM CDT
Investors in Northwest Biotherapeutics Inc saw new options become available this week, for the June 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new June 19th contracts and...
NWBO: 8.36 (-0.39)
NW Bio Featured In Presentations At the American Association for Cancer Research Annual Meeting
PR Newswire - Mon Apr 20, 5:00AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"
, a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that its clinical programs with DCVax-L for Glioblastoma multiforme (GBM) brain cancer, and with DCVax-Direct for all types of inoperable solid tumors, will be featured in presentations on Monday, April 20, 2015, at the American Association for Cancer Research Annual Meeting 2015 taking place in Philadelphia.
NWBO: 8.36 (-0.39)
NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies"
PR Newswire - Thu Apr 16, 5:00AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio" , a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that it has been included in the Loncar Cancer Immunotherapy Index (LCINDX), a professional index recently established to help investors better track the immunotherapy field within the biotechnology space.
NWBO: 8.36 (-0.39)
Global & USA Cancer Immunotherapy Market Analysis 2015-2020
M2 - Fri Apr 10, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6tkxf/global_and_usa) has announced the addition of the "GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors" report to their offering. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Scope - An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies. - Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines. - Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs. - Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market). - Insight into the various immunotherapeutics available for specific cancer types. - Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics. - Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs. - Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs. - Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe. - Summary table to identify the category of immunotherapy drug offered by the 76 companies. Companies Mentioned - 30 of the 75 Companies Featured - Ablynx NV - Activartis Biotech GmbH - Advaxis Inc. - Aduro BioTech Inc. - Agenus Inc. - AlphaVax Inc. - Amgen Inc. - Antigen Express Inc. - Argos Therapeutics Inc. - Bavarian Nordic A/S - Bellicum Pharmaceuticals Inc. - Biogen Idec Inc.x - Biovest International Inc. - Genmab AS - GlaxoSmithKline - Gliknik Inc. - GlobeImmune Inc. - Heat Biologics Inc. - Immatics Biotechnologies GmbH - ImmunoCellular Therapeutics Ltd. - Merrimack Pharmaceuticals Inc. - Morphotek Inc. - NewLink Genetics Corp. - Northwest Biotherapeutics Inc. - NovaRx Corp. - OncoPep Inc. - Oncothyreon Inc. - OSE Pharma SA - Viventia Biotechnologies Inc. - Wilex AG For more information visit http://www.researchandmarkets.com/research/z6...al_and_usa
HTBX: 7.71 (-0.64), BIIB: 423.57 (+1.46), NWBO: 8.36 (-0.39), ADXS: 22.18 (+0.10), ADRO: 38.17 (-0.50), AMGN: 169.10 (+0.64), GSK: 46.57 (-0.67), ONTY: 1.80 (+0.03), IMUC: 0.53 (+0.02), MACK: 13.44 (+0.18), GBIM: 8.46 (+0.46), ARGS: 8.48 (-0.11), BLCM: 28.55 (+2.59), NLNK: 53.12 (-0.07)
NW BIO TO PRESENT AT WORLD VACCINE CONGRESS 2015
PR Newswire - Thu Apr 09, 7:00AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio" , a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Leslie J. Goldman, Senior Vice President Business Development, will present at the World Vaccine Congress 2015 that is being held in Washington, DC from April 7- 9.
NWBO: 8.36 (-0.39)
Cancer Targeted Therapy Market & Clinical Insight 2015
M2 - Thu Apr 09, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq2wq/cancer_targeted) has announced the addition of the "Cancer Targeted Therapy Market & Clinical Insight 2015" report to their offering. Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large molecule cancer targeted therapeutics having better pharmacological profiles. Clinical Insight on Cancer Targeted Therapies Pipeline Covered in Report: - Cancer Targeted Tyrosine Kinase Inhibitors Pipeline: 388 TKI - Cancer Targeted Angiogenesis Inhibitors Pipeline: 166 Angiogenesis Inhibitors - Cancer Vaccines Pipeline: 289 Cancer Vaccines - Cancer Targeted Monoclonal Antibodies: 605 mAb - Oncogene Inhibitors Pipeline: 185 oncogene inhibitors Cancer Targeted Therapy Market & Clinical Insight Report Highlight: - Introduction & Categorization of Cancer Targeted Therapies - Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies - Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase - Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline - Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies - Global Cancer Targeted Therapeutics Market Dynamics - Future Prospects of Cancer Targeted Therapies Key Topics Covered: 1. Introduction to Cancer Targeted Therapeutics 2. Need for Cancer Targeted Therapeutics 3. Categorization of Cancer Targeted Therapies 4. Consideration of Cancer Vaccines as Targeted Therapeutics 5. Mechanism of Cancer Vaccines 6. Mechanisms of Cancer Targeted Monoclonal Antibodies 7. Mechanism of Cancer Targeted Tyrosine Kinase Therapeutics 8. Mechanism of Oncogene Inhibitors 9. Global Cancer Targeted Therapy Market Overview 10. Global Cancer Targeted Therapeutics Market Dynamics 11. Future Prospects of Cancer Targeted Therapeutics 12. Cancer Targeted Monoclonal Antibodies Pipeline by Company, Indication & Phase 13. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country 14. Global Cancer Vaccines Clinical Pipeline Insight by Company, Indication & Phase 15. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 16. Oncogene Inhibitors Pipeline by Company, Indication & Phase 17. Marketed Oncogene Inhibitors by Company & Indication 18. Cancer Targeted Tyrosine Kinase Clinical Trial by Company, Indication & Phase 19. Marketed Cancer Targeted Tyrosine Kinase Inhibitors 20. Cancer Targeted Angiogenesis Inhibitors Therapy Pipeline by Company, Phase & Indication 21. Marketed Cancer Targeted Angiogenesis Inhibitors 22. Competitive Landscape - Advaxis - Bind Therapeutics - Boehringer Ingelheim - Bristol Mayer Squibb - Celldex Therapeutics - Dendreon Corporation - Eli Lily - GalaxoSmithKline - Galena Biopharma - Genetech - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Johnson & Johnson - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Merck - Novartis - Peregrine Pharmaceuticals - Pfizer - Roche - Sanofi - Seattle Genetics - Teva For more information visit http://www.researchandmarkets.com/research/4l...r_targeted
JNJ: 100.43 (+0.13), INO: 10.39 (-0.09), NWBO: 8.36 (-0.39), MRK: 57.69 (+0.03), CLDX: 28.95 (+1.08), NLNK: 53.12 (-0.07), GALE: 1.39 (unch), IMUC: 0.53 (+0.02), NVS: 103.45 (-0.62)
Disruptive Innovation Changing the Fight Against Cancer
Cheryl Swanson, The Motley Fool - Motley Fool - Sun Apr 05, 12:02PM CDT
We all know someone who is battling cancer. It's a terrible disease, with over 1.6 million new cases diagnosed every year in the U.S. Cancer deaths per 100,000 people have been slowly declining since 1991, but tragically, modern treatment often has...
NWBO: 8.36 (-0.39), MRK: 57.69 (+0.03), CLDX: 28.95 (+1.08), AZN: 73.35 (+0.65), XON: 44.53 (+0.36), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62)
NW Bio enters into USD40m equity investment agreement with Woodford Funds
M2 - Fri Apr 03, 5:51AM CDT
Biotechnology company Northwest Biotherapeutics (NasdaqCM:NWBO) reported on Thursday the launch of a USD40m financing agreement with Woodford Investment Management (agent) for the CF Woodford Equity Income Fund and other clients.
NWBO: 8.36 (-0.39)
NW Bio Announces $40 Million Financing
PR Newswire - Thu Apr 02, 10:55AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that today the Company entered into agreement with Woodford Investment Management LLP ("Woodford" , as agent for the CF Woodford Equity Income Fund and other clients, for financing of $40 million.
NWBO: 8.36 (-0.39)
Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm
at The Street - Thu Apr 02, 4:57AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
ZIOP: 10.88 (+0.03), NWBO: 8.36 (-0.39), XON: 44.53 (+0.36)
Northwest Biotherapeutics: Encouraging Survival Results In 51 Glioblastoma Multiforme Patients
Smith On Stocks - Seeking Alpha - Tue Mar 31, 8:48AM CDT
Executive Summary Northwest Biotherapeutics (NASDAQ: NWBO ) has just presented data on 51 patients whom investigators originally intended to enroll in the ongoing, critically important, 348 patients phase 3 trial of DCVax-L in newly diagnosed...
NWBO: 8.36 (-0.39), KITE: 57.56 (-1.43), CLDX: 28.95 (+1.08), JUNO: 55.72 (-0.68)
Northwest Bio's CTO Bosch presents brain cancer survival data for DCVax-L
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 11:57AM CDT
NWBO: 8.36 (-0.39)
NW BIO REPORTS PROMISING SURVIVAL DATA IN 51 GBM PATIENTS TREATED WITH DCVAX®-L
PR Newswire - Fri Mar 27, 8:00AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio" , a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Dr. Marnix Bosch, the Company's Chief Technical Officer, presented encouraging survival data on 51 Glioblastoma multiforme (GBM) brain cancer patients treated with DCVax®-L. The data showed substantially longer than expected survival in patients with apparent early progression (recurrence) of their cancer, including patients with such aggressive cancer that the tumor was already re-growing by the end of 6 weeks of daily radiotherapy and chemotherapy after surgical removal of the original tumor.
NWBO: 8.36 (-0.39)
NW Bio To Present At The 2nd Immunotherapy Of Cancer Conference, ITOC-2
PR Newswire - Tue Mar 24, 9:42AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio" , a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Dr. Marnix Bosch, Chief Technical Officer, will present at the 2nd Immunotherapy of Cancer Conference, ITOC-2, being held in Munich, Germany from March 25-27, 2015.
NWBO: 8.36 (-0.39)
Jim Cramer's 'Mad Money' Recap: 5 'What If' Scenarios That Could Change Markets
at The Street - Mon Mar 23, 7:25PM CDT
Every good investor needs to challenge his or her thinking, Cramer says.
CY: 13.57 (+0.11), MMM: 164.67 (+0.67), MU: 29.50 (+0.95), NWBO: 8.36 (-0.39), SWKS: 96.83 (+1.41), FB: 84.63 (+1.01), STX: 58.23 (-0.18), XON: 44.53 (+0.36), WSM: 76.08 (-0.66), NXPI: 102.69 (+1.45), WDC: 100.31 (+0.63), INTC: 32.70 (+0.27), QRVO: 74.48 (+0.41), AAVL: 38.93 (-0.42), TWTR: 51.73 (+0.41), AAPL: 128.62 (+1.71), AVGO: 127.89 (+4.79), SNDK: 68.48 (+0.56)
Sonic Corp. Is A Terrific Stock - Cramer's Lightning Round (3/19/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Mar 20, 4:04AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, March 19. Bullish Calls: Duke Energy (NYSE: DUK ): "All the utilities have been slammed here over the false fears that the Fed is going to...
CBI: 49.62 (-1.62),
72.52 (+0.43), NWBO: 8.36 (-0.39), BCRX: 10.62 (-0.09), SWKS: 96.83 (+1.41), SONC: 30.75 (+0.14), DUK: 78.30 (+0.23), INVN: 16.13 (+0.42)
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 48.35 (+1.23), NWBO: 8.36 (-0.39), ZIOP: 10.88 (+0.03), PCYC: 256.98 (-0.77), CVM: 0.88 (+0.07), PFE: 34.93 (+0.04), CLDX: 28.95 (+1.08), IMGN: 9.96 (+0.01), BMY: 66.60 (-0.21), RIGL: 4.24 (+0.07), INO: 10.39 (-0.09), KITE: 57.56 (-1.43), LH: 126.26 (+0.35), ABBV: 64.52 (+0.91), PBYI: 225.63 (-4.24)
U.K. Regulators Grant Early Access to Merck Skin Cancer Drug, but Where Is Northwest Bio?
at The Street - Wed Mar 11, 9:45AM CDT
Skin cancer patients in Britain can be treated with Merck's Keytruda before the cancer immunotherapy drug is approved there under a new early access plan announced Wednesday.
NWBO: 8.36 (-0.39), MRK: 57.69 (+0.03), BMY: 66.60 (-0.21)
Northwest Bio cleared to begin DCVax-L study in Canada
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 3:31PM CST
NWBO: 8.36 (-0.39)
Northwest Has A Differentiated Technology Platform In The Emerging Immuno-Oncology Landscape
Smith On Stocks - Seeking Alpha - Fri Feb 06, 11:08AM CST
Investment Overview Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential role of personalized immunotherapy drugs in the treatment of cancer. She was prominently featured in the ...
NWBO: 8.36 (-0.39), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68)
Interesting NWBO Put And Call Options For June 19th
StockOptionsChannel.com - Wed Apr 22, 10:19AM CDT
Investors in Northwest Biotherapeutics Inc saw new options become available this week, for the June 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new June 19th contracts and...
NWBO: 8.36 (-0.39)
NW Bio Featured In Presentations At the American Association for Cancer Research Annual Meeting
PR Newswire - Mon Apr 20, 5:00AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"
, a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that its clinical programs with DCVax-L for Glioblastoma multiforme (GBM) brain cancer, and with DCVax-Direct for all types of inoperable solid tumors, will be featured in presentations on Monday, April 20, 2015, at the American Association for Cancer Research Annual Meeting 2015 taking place in Philadelphia. NWBO: 8.36 (-0.39)
NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies"
PR Newswire - Thu Apr 16, 5:00AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"
, a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that it has been included in the Loncar Cancer Immunotherapy Index (LCINDX), a professional index recently established to help investors better track the immunotherapy field within the biotechnology space. NWBO: 8.36 (-0.39)
Global & USA Cancer Immunotherapy Market Analysis 2015-2020
M2 - Fri Apr 10, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6tkxf/global_and_usa) has announced the addition of the "GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors" report to their offering. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Scope - An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies. - Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines. - Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs. - Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market). - Insight into the various immunotherapeutics available for specific cancer types. - Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics. - Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs. - Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs. - Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe. - Summary table to identify the category of immunotherapy drug offered by the 76 companies. Companies Mentioned - 30 of the 75 Companies Featured - Ablynx NV - Activartis Biotech GmbH - Advaxis Inc. - Aduro BioTech Inc. - Agenus Inc. - AlphaVax Inc. - Amgen Inc. - Antigen Express Inc. - Argos Therapeutics Inc. - Bavarian Nordic A/S - Bellicum Pharmaceuticals Inc. - Biogen Idec Inc.x - Biovest International Inc. - Genmab AS - GlaxoSmithKline - Gliknik Inc. - GlobeImmune Inc. - Heat Biologics Inc. - Immatics Biotechnologies GmbH - ImmunoCellular Therapeutics Ltd. - Merrimack Pharmaceuticals Inc. - Morphotek Inc. - NewLink Genetics Corp. - Northwest Biotherapeutics Inc. - NovaRx Corp. - OncoPep Inc. - Oncothyreon Inc. - OSE Pharma SA - Viventia Biotechnologies Inc. - Wilex AG For more information visit http://www.researchandmarkets.com/research/z6...al_and_usa
HTBX: 7.71 (-0.64), BIIB: 423.57 (+1.46), NWBO: 8.36 (-0.39), ADXS: 22.18 (+0.10), ADRO: 38.17 (-0.50), AMGN: 169.10 (+0.64), GSK: 46.57 (-0.67), ONTY: 1.80 (+0.03), IMUC: 0.53 (+0.02), MACK: 13.44 (+0.18), GBIM: 8.46 (+0.46), ARGS: 8.48 (-0.11), BLCM: 28.55 (+2.59), NLNK: 53.12 (-0.07)
NW BIO TO PRESENT AT WORLD VACCINE CONGRESS 2015
PR Newswire - Thu Apr 09, 7:00AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"
, a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Leslie J. Goldman, Senior Vice President Business Development, will present at the World Vaccine Congress 2015 that is being held in Washington, DC from April 7- 9. NWBO: 8.36 (-0.39)
Cancer Targeted Therapy Market & Clinical Insight 2015
M2 - Thu Apr 09, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq2wq/cancer_targeted) has announced the addition of the "Cancer Targeted Therapy Market & Clinical Insight 2015" report to their offering. Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large molecule cancer targeted therapeutics having better pharmacological profiles. Clinical Insight on Cancer Targeted Therapies Pipeline Covered in Report: - Cancer Targeted Tyrosine Kinase Inhibitors Pipeline: 388 TKI - Cancer Targeted Angiogenesis Inhibitors Pipeline: 166 Angiogenesis Inhibitors - Cancer Vaccines Pipeline: 289 Cancer Vaccines - Cancer Targeted Monoclonal Antibodies: 605 mAb - Oncogene Inhibitors Pipeline: 185 oncogene inhibitors Cancer Targeted Therapy Market & Clinical Insight Report Highlight: - Introduction & Categorization of Cancer Targeted Therapies - Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies - Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase - Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline - Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies - Global Cancer Targeted Therapeutics Market Dynamics - Future Prospects of Cancer Targeted Therapies Key Topics Covered: 1. Introduction to Cancer Targeted Therapeutics 2. Need for Cancer Targeted Therapeutics 3. Categorization of Cancer Targeted Therapies 4. Consideration of Cancer Vaccines as Targeted Therapeutics 5. Mechanism of Cancer Vaccines 6. Mechanisms of Cancer Targeted Monoclonal Antibodies 7. Mechanism of Cancer Targeted Tyrosine Kinase Therapeutics 8. Mechanism of Oncogene Inhibitors 9. Global Cancer Targeted Therapy Market Overview 10. Global Cancer Targeted Therapeutics Market Dynamics 11. Future Prospects of Cancer Targeted Therapeutics 12. Cancer Targeted Monoclonal Antibodies Pipeline by Company, Indication & Phase 13. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country 14. Global Cancer Vaccines Clinical Pipeline Insight by Company, Indication & Phase 15. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 16. Oncogene Inhibitors Pipeline by Company, Indication & Phase 17. Marketed Oncogene Inhibitors by Company & Indication 18. Cancer Targeted Tyrosine Kinase Clinical Trial by Company, Indication & Phase 19. Marketed Cancer Targeted Tyrosine Kinase Inhibitors 20. Cancer Targeted Angiogenesis Inhibitors Therapy Pipeline by Company, Phase & Indication 21. Marketed Cancer Targeted Angiogenesis Inhibitors 22. Competitive Landscape - Advaxis - Bind Therapeutics - Boehringer Ingelheim - Bristol Mayer Squibb - Celldex Therapeutics - Dendreon Corporation - Eli Lily - GalaxoSmithKline - Galena Biopharma - Genetech - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Johnson & Johnson - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Merck - Novartis - Peregrine Pharmaceuticals - Pfizer - Roche - Sanofi - Seattle Genetics - Teva For more information visit http://www.researchandmarkets.com/research/4l...r_targeted
JNJ: 100.43 (+0.13), INO: 10.39 (-0.09), NWBO: 8.36 (-0.39), MRK: 57.69 (+0.03), CLDX: 28.95 (+1.08), NLNK: 53.12 (-0.07), GALE: 1.39 (unch), IMUC: 0.53 (+0.02), NVS: 103.45 (-0.62)
Disruptive Innovation Changing the Fight Against Cancer
Cheryl Swanson, The Motley Fool - Motley Fool - Sun Apr 05, 12:02PM CDT
We all know someone who is battling cancer. It's a terrible disease, with over 1.6 million new cases diagnosed every year in the U.S. Cancer deaths per 100,000 people have been slowly declining since 1991, but tragically, modern treatment often has...
NWBO: 8.36 (-0.39), MRK: 57.69 (+0.03), CLDX: 28.95 (+1.08), AZN: 73.35 (+0.65), XON: 44.53 (+0.36), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62)
NW Bio enters into USD40m equity investment agreement with Woodford Funds
M2 - Fri Apr 03, 5:51AM CDT
Biotechnology company Northwest Biotherapeutics (NasdaqCM:NWBO) reported on Thursday the launch of a USD40m financing agreement with Woodford Investment Management (agent) for the CF Woodford Equity Income Fund and other clients.
NWBO: 8.36 (-0.39)
NW Bio Announces $40 Million Financing
PR Newswire - Thu Apr 02, 10:55AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that today the Company entered into agreement with Woodford Investment Management LLP ("Woodford" , as agent for the CF Woodford Equity Income Fund and other clients, for financing of $40 million. NWBO: 8.36 (-0.39)
Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm
at The Street - Thu Apr 02, 4:57AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
ZIOP: 10.88 (+0.03), NWBO: 8.36 (-0.39), XON: 44.53 (+0.36)
Northwest Biotherapeutics: Encouraging Survival Results In 51 Glioblastoma Multiforme Patients
Smith On Stocks - Seeking Alpha - Tue Mar 31, 8:48AM CDT
Executive Summary Northwest Biotherapeutics (NASDAQ: NWBO ) has just presented data on 51 patients whom investigators originally intended to enroll in the ongoing, critically important, 348 patients phase 3 trial of DCVax-L in newly diagnosed...
NWBO: 8.36 (-0.39), KITE: 57.56 (-1.43), CLDX: 28.95 (+1.08), JUNO: 55.72 (-0.68)
Northwest Bio's CTO Bosch presents brain cancer survival data for DCVax-L
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 11:57AM CDT
NWBO: 8.36 (-0.39)
NW BIO REPORTS PROMISING SURVIVAL DATA IN 51 GBM PATIENTS TREATED WITH DCVAX®-L
PR Newswire - Fri Mar 27, 8:00AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"
, a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Dr. Marnix Bosch, the Company's Chief Technical Officer, presented encouraging survival data on 51 Glioblastoma multiforme (GBM) brain cancer patients treated with DCVax®-L. The data showed substantially longer than expected survival in patients with apparent early progression (recurrence) of their cancer, including patients with such aggressive cancer that the tumor was already re-growing by the end of 6 weeks of daily radiotherapy and chemotherapy after surgical removal of the original tumor. NWBO: 8.36 (-0.39)
NW Bio To Present At The 2nd Immunotherapy Of Cancer Conference, ITOC-2
PR Newswire - Tue Mar 24, 9:42AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"
, a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Dr. Marnix Bosch, Chief Technical Officer, will present at the 2nd Immunotherapy of Cancer Conference, ITOC-2, being held in Munich, Germany from March 25-27, 2015. NWBO: 8.36 (-0.39)
Jim Cramer's 'Mad Money' Recap: 5 'What If' Scenarios That Could Change Markets
at The Street - Mon Mar 23, 7:25PM CDT
Every good investor needs to challenge his or her thinking, Cramer says.
CY: 13.57 (+0.11), MMM: 164.67 (+0.67), MU: 29.50 (+0.95), NWBO: 8.36 (-0.39), SWKS: 96.83 (+1.41), FB: 84.63 (+1.01), STX: 58.23 (-0.18), XON: 44.53 (+0.36), WSM: 76.08 (-0.66), NXPI: 102.69 (+1.45), WDC: 100.31 (+0.63), INTC: 32.70 (+0.27), QRVO: 74.48 (+0.41), AAVL: 38.93 (-0.42), TWTR: 51.73 (+0.41), AAPL: 128.62 (+1.71), AVGO: 127.89 (+4.79), SNDK: 68.48 (+0.56)
Sonic Corp. Is A Terrific Stock - Cramer's Lightning Round (3/19/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Mar 20, 4:04AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, March 19. Bullish Calls: Duke Energy (NYSE: DUK ): "All the utilities have been slammed here over the false fears that the Fed is going to...
CBI: 49.62 (-1.62),
72.52 (+0.43), NWBO: 8.36 (-0.39), BCRX: 10.62 (-0.09), SWKS: 96.83 (+1.41), SONC: 30.75 (+0.14), DUK: 78.30 (+0.23), INVN: 16.13 (+0.42) Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 48.35 (+1.23), NWBO: 8.36 (-0.39), ZIOP: 10.88 (+0.03), PCYC: 256.98 (-0.77), CVM: 0.88 (+0.07), PFE: 34.93 (+0.04), CLDX: 28.95 (+1.08), IMGN: 9.96 (+0.01), BMY: 66.60 (-0.21), RIGL: 4.24 (+0.07), INO: 10.39 (-0.09), KITE: 57.56 (-1.43), LH: 126.26 (+0.35), ABBV: 64.52 (+0.91), PBYI: 225.63 (-4.24)
U.K. Regulators Grant Early Access to Merck Skin Cancer Drug, but Where Is Northwest Bio?
at The Street - Wed Mar 11, 9:45AM CDT
Skin cancer patients in Britain can be treated with Merck's Keytruda before the cancer immunotherapy drug is approved there under a new early access plan announced Wednesday.
NWBO: 8.36 (-0.39), MRK: 57.69 (+0.03), BMY: 66.60 (-0.21)
Northwest Bio cleared to begin DCVax-L study in Canada
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 3:31PM CST
NWBO: 8.36 (-0.39)
Northwest Has A Differentiated Technology Platform In The Emerging Immuno-Oncology Landscape
Smith On Stocks - Seeking Alpha - Fri Feb 06, 11:08AM CST
Investment Overview Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential role of personalized immunotherapy drugs in the treatment of cancer. She was prominently featured in the ...
NWBO: 8.36 (-0.39), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68)
